Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 2

1(20.0%)

5Total

N/A(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04175327Active Not Recruiting

Prospective and Non-randomized Registry of CardioCel 3D

Role: lead

NCT03176225Not ApplicableCompleted

Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac Repair

Role: lead

NCT03173703Not ApplicableActive Not Recruiting

Evaluate Safety and Effectiveness of XenoSure® Biological Patch in the Application of Peripheral Vascular Repair

Role: lead

NCT04906824Active Not Recruiting

Post-Market Registry in Europe and US for the Use of VascuCelTM

Role: lead

NCT05386342Not ApplicableRecruiting

A PMCF Study Confirm the Performance and Safety of the TufTex Over-the-Wire (OTW) Embolectomy Catheters

Role: lead

NCT04620889Completed

LeMaitre LifeSpan® ePTFE Vascular Graft Retrospective Registry

Role: lead

NCT05386277Not ApplicableRecruiting

A PMCF Study to Confirm the Performance and Safety of the LeMaitre® TufTex Single Lumen Embolectomy Catheter

Role: lead

NCT00131872Phase 2Terminated

Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access Grafts

Role: lead

NCT05350358Completed

LeMaitre® CARDIAL Dialine II Post Market Study

Role: collaborator

All 9 trials loaded